Albanell J, Lonardo F, Rusch V, Engelhardt M, Langenfeld J, Han W, Klimstra D, Venkatraman E, Moore M A, Dmitrovsky E
Laboratory of Developmental Hematopoiesis, Memorial Hospital and Sloan-Kettering Institute, Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA.
J Natl Cancer Inst. 1997 Nov 5;89(21):1609-15. doi: 10.1093/jnci/89.21.1609.
Telomerase enzyme activity is not detected in most normal cells, a phenomenon believed to be associated with limitations on cellular proliferation. Since this activity is detected in nearly all human tumors, including non-small-cell lung cancers, it has been suggested that telomerase activation may be coupled to acquisition of the malignant phenotype. In this study, we determined whether telomerase activity was associated with tumor pathologic stage, tumor cell proliferation rates, and clinical outcome in a cohort of patients with resected non-small-cell lung cancer for whom long-term follow-up was available.
Primary tumor specimens from 99 patients treated with surgery alone and six patients treated with surgery after chemotherapy were analyzed. Telomerase activity was measured by means of a modified Telomeric Repeat Amplification Protocol (TRAP) assay. Southern blot analysis of terminal restriction fragments was used to evaluate telomere length. Immunohistochemical analysis of Ki-67, a proliferation-associated nuclear antigen, was used to assess tumor cell proliferation.
Telomerase activity was detected in 84 of the 99 tumors treated with surgery alone; this activity was not detected in specimens of adjacent, benign lung tissue. Telomerase was detected in only three of six tumors resected after chemotherapy. For the surgery-alone group, statistically significant positive associations were found between the level of telomerase activity and tumor stage, lymph node metastasis, pathologic TNM (tumor-node-metastasis) stage, and Ki-67 immunostaining; a statistically significant inverse association was found between telomerase activity and patient age. No statistically significant differences in telomere length were found in relation telomerase activity or pathologic stage. Telomerase activity was not found to be associated with clinical outcome in a multivariate Cox proportional hazards analysis adjusted for tumor stage and lymph node status.
High telomerase activity is detected frequently in primary non-small-cell lung cancers that exhibit high tumor cell proliferation rates and advanced pathologic stage.
在大多数正常细胞中未检测到端粒酶活性,这一现象被认为与细胞增殖受限有关。由于在几乎所有人类肿瘤中,包括非小细胞肺癌,都检测到了这种活性,因此有人提出端粒酶激活可能与恶性表型的获得有关。在本研究中,我们确定了在一组接受手术切除且有长期随访资料的非小细胞肺癌患者中,端粒酶活性是否与肿瘤病理分期、肿瘤细胞增殖率及临床结局相关。
分析了99例仅接受手术治疗的患者以及6例化疗后接受手术治疗的患者的原发性肿瘤标本。采用改良的端粒重复序列扩增法(TRAP)检测端粒酶活性。通过对末端限制片段的Southern印迹分析来评估端粒长度。采用免疫组织化学分析法检测增殖相关核抗原Ki-67,以评估肿瘤细胞增殖情况。
在99例仅接受手术治疗的肿瘤中,有84例检测到端粒酶活性;在相邻的良性肺组织标本中未检测到这种活性。在化疗后切除的6例肿瘤中,仅3例检测到端粒酶。对于仅接受手术治疗的组,端粒酶活性水平与肿瘤分期、淋巴结转移、病理TNM(肿瘤-淋巴结-转移)分期及Ki-67免疫染色之间存在统计学显著的正相关;端粒酶活性与患者年龄之间存在统计学显著的负相关。在端粒酶活性或病理分期方面,未发现端粒长度有统计学显著差异。在对肿瘤分期和淋巴结状态进行校正的多变量Cox比例风险分析中,未发现端粒酶活性与临床结局相关。
在肿瘤细胞增殖率高且病理分期晚的原发性非小细胞肺癌中,经常检测到高端粒酶活性。